2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…2018 American Transplant Congress
Risk Factors for Postoperative Bleeding after Lung Transplantation
Bleeding complications after lung transplantation (LuTX) are associated with increased morbidity. Risk factors for postoperative bleeding complications after LuTX have not yet been reported. In…2018 American Transplant Congress
Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients
University of North Carolina, Chapel Hill.
Purpose of this study is to determine safety of Alemtuzumab (Ab) in elderly kidney recipients.MethodsThis is a retrospective single center cohort analysis concerning kidney transplant…2018 American Transplant Congress
Water-Jet Dissection for Donor Hepatectomy during Living Donor Liver Transplantation
Background The most important issue in living donor liver transplantation (LDLT) is donor safety. Although donor hepatectomy has evolved technically over the years, it is…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Laparoscopic Donor Nephrectomy Safety: Experience of 500 Cases in Hispanic Population at a Single Institution
Transplantation Surgery, Colombiana de Trasplantes, Bogota, Colombia.
Background: Laparoscopic live donor nephrectomy (LDN) has become the best option in living donation because its safety and low rate of complications. This report aims…2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…2018 American Transplant Congress
Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients
University of Iowa Hospitals and Clinics, Iowa City, IA.
Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…2018 American Transplant Congress
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies
Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…2018 American Transplant Congress
Pediatric Kidney Transplant in Norway – Results after Switching from Midline to Retroperitoneal Approach in Recipients below 25 kg
Section for Transplant Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Introduction: Pediatric kidney transplants demand a high level of surgical and medical involvement and skill. In Norway, all organ transplants are centralized and performed at…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 19
- Next Page »